BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filippone EJ, Farber JL. Membranous nephropathy in the kidney allograft. Clin Transplant 2016;30:1394-402. [DOI: 10.1111/ctr.12847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Leon J, Pérez-sáez MJ, Batal I, Beck LH, Rennke HG, Canaud G, Legendre C, Pascual J, Riella LV. Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management. Transplantation 2019;103:1990-2002. [DOI: 10.1097/tp.0000000000002758] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
2 de Sousa MV, Fernandes LGR, de Freitas LLL, Zollner RDL, Mazzali M. De Novo Membranous Nephropathy Associated With Antibody-Mediated Rejection in Kidney Transplant Recipients. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2021.11.041] [Reference Citation Analysis]
3 Münch J, Krüger BM, Weimann A, Wiech T, Reinhard L, Hoxha E, Pfister F, Halbritter J. Posttransplant nephrotic syndrome resulting from NELL1-positive membranous nephropathy. Am J Transplant 2021;21:3175-9. [PMID: 33866674 DOI: 10.1111/ajt.16610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Xipell M, Rodas LM, Villarreal J, Molina A, Reinoso-Moreno J, Blasco M, Poch E, Diekmann F, Campistol JM, Quintana LF. The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation. Clin Kidney J 2018;11:422-8. [PMID: 29988247 DOI: 10.1093/ckj/sfx128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Katsuma A, Nakada Y, Yamamoto I, Horita S, Katsumata H, Kobayashi A, Unagami K, Okumi M, Ishida H, Yokoo T, Yamaguchi Y, Tanabe K; Japan Academic Consortium of Kidney Transplantation (JACK). Clinicopathological study of de novo membranous nephropathy of ‘stage 0’ after kidney transplantation: De novo membranous nephropathy stage 0. Nephrology 2018;23:63-9. [DOI: 10.1111/nep.13274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Li J, Liu B, Xue H, Zhou QQ, Peng L. miR-217 Is a Useful Diagnostic Biomarker and Regulates Human Podocyte Cells Apoptosis via Targeting TNFSF11 in Membranous Nephropathy. Biomed Res Int 2017;2017:2168767. [PMID: 29214160 DOI: 10.1155/2017/2168767] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
7 Cravedi P, Jarque M, Angeletti A, Favà À, Cantarelli C, Bestard O. Immune-Monitoring Disease Activity in Primary Membranous Nephropathy. Front Med (Lausanne) 2019;6:241. [PMID: 31788474 DOI: 10.3389/fmed.2019.00241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol 2017;12:983-97. [PMID: 28550082 DOI: 10.2215/CJN.11761116] [Cited by in Crossref: 175] [Cited by in F6Publishing: 89] [Article Influence: 35.0] [Reference Citation Analysis]